Elaine E.L. Wang has been the Director at Boehringer Ingelheim Pharmaceuticals Inc. for a total of 8 years now but has been in the Pharmaceutical Industry since 1999. Elaine works in the Respiratory Division supporting understanding around the diagnosis and management of Idiopathic Pulmonary Fibrosis (IPF), a rare lethal disease. She is involved in research for the drug, nintedanib, in the treatment of IPF. Elaine’s responsibilities include conducting studies where endpoints are more meaningful to patients and payers than pulmonary function tests, which are the basis for licensure. She interfaces with marketing in developing messages, and prepares and delivers training sessions. Elaine interacts with Advisory Boards and clinical experts representing her company to understand knowledge needs and providing information on nintedanib and IPF. She belongs to the nintedanib MLR committee to ensure that communications are medically accurate.

Elaine’s goal is to develop products with the best benefit and risk balance for patients in the most timely manner. She served as a clinical project leader between 2008 and 2014 at BI in anti-viral (HIV and HCV) clinical development, and development of apsoriasis biologic, in licensing evaluations, and interface with R and D. She has experience from pre-clinical to proof-of-concept programs and pivotal studies for product submission. Elaine worked at Replidyne from 2006 to 2008 and was in charge of the pediatric and adult clinical development of an oral and a topical antibiotics. Elaine is very proud of the fact that she works for the major privately owned global pharmaceutical company in the world successfully providing much needed products to patients.